keyword
MENU ▼
Read by QxMD icon Read
search

Mullerian cancer

keyword
https://www.readbyqxmd.com/read/29137935/prostatic-adenocarcinoma-in-the-setting-of-persistent-m%C3%A3-llerian-duct-syndrome-a-case-report
#1
Zulfia McCroskey, Tracie M Koen, David J Lim, Mukul K Divatia, Steven S Shen, Alberto G Ayala, Jae Y Ro
Persistent Müllerian Duct Syndrome (PMDS) is a form of disordered sex development in which rudimentary Müllerian structures are identified in phenotypically and genotypically normal males. It is caused by defects in the anti-Müllerian hormone (AMH) system. Since patients with PMDS present with undescended testes, testosterone production by Leydig cells later in life is often decreased. The role of androgens in prostate cancerogenesis is well known. Cryptorchid testes and diminished testosterone levels in post pubertal life in patients with PMDS play a protective role against prostate cancer, and hence, prostate cancer is a rare event in patients with PMDS...
November 11, 2017: Human Pathology
https://www.readbyqxmd.com/read/29136604/extragenital-malignant-mixed-mesodermal-tumor-a-case-report
#2
Mauro Del Papa, Gabriele D'Amata, Fulvio Manzi, Luca Musmeci, Marco Crovaro, Carlo Buonocore, Gaetano Florio, Andrea Giannetti
INTRODUCTION: Primary malignant mixed mesodermal tumor (MMMt, also called malignant mixed Mullerian tumor and designated in the WHO classification of female genital tract neoplasms as carcinosarcoma) is an infrequent tumor that develops usually in the uterus and more rarely in the ovary. Extragenital tumor, including primary peritoneal MMMt, is an extremely rare and aggressive neoplasm with only few case reported in the literature. PRESENTATION OF CASE: We report a case of a 70-year's old female who presented with nausea and abdominal discomfort for 6 months...
November 9, 2017: International Journal of Surgery Case Reports
https://www.readbyqxmd.com/read/29117576/the-utility-of-anti-m%C3%A3-llerian-hormone-in-the-diagnosis-and-prediction-of-loss-of-ovarian-function-following-chemotherapy-for-early-breast-cancer
#3
R A Anderson, J Mansi, R E Coleman, D J A Adamson, R C F Leonard
AIM: Chemotherapy results in permanent loss of ovarian function in some premenopausal women. Accurate identification in women with hormone-sensitive early breast cancer (eBC) would allow optimisation of subsequent endocrine treatment. We sought to assess whether analysis of anti-Müllerian hormone (AMH) using a sensitive automated assay could identify women who would not regain ovarian function after chemotherapy. METHODS: Data from women in the Ovarian Protection Trial in Premenopausal Breast Cancer Patients (OPTION) trial of goserelin (a gonadotrophin-releasing hormone (GnRH) analogue) for ovarian protection were analysed...
November 5, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/29093011/primary-immunoprevention-of-epithelial-ovarian-carcinoma-by-vaccination-against-the-extracellular-domain-of-anti-m%C3%A3-llerian-hormone-receptor-ii
#4
Suparna Mazumder, Justin M Johnson, Valerie Swank, Nina Dvorina, Elizabeth Martelli, Jennifer Ko, Vincent K Tuohy
Epithelial ovarian carcinoma (EOC) is the most prevalent form of ovarian cancer in the United States, representing approximately 85% of all cases and causing more deaths than any other gynecologic malignancy. We propose that optimized control of EOC requires the incorporation of a vaccine capable of inducing safe and effective preemptive immunity in cancer-free women. In addition, we hypothesize that ovarian-specific self-proteins that are "retired" from autoimmune-inducing expression levels as ovaries age but are expressed at high levels in emerging EOC may serve as vaccine targets for mediating safe and effective primary immunoprevention...
November 2017: Cancer Prevention Research
https://www.readbyqxmd.com/read/29045555/reproductive-potential-and-performance-of-fertility-preservation-strategies-in-brca-mutated-breast-cancer-patients
#5
M Lambertini, O Goldrat, A R Ferreira, J Dechene, H A Azim, J Desir, A Delbaere, M-D t'Kint de Roodenbeke, E de Azambuja, M Ignatiadis, I Demeestere
BackgroundPreclinical evidence suggests a possible negative impact of deleterious BRCA mutations on female fertility. However, limited and rather conflicting clinical data are available. This study assessed the reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients.Patients and MethodsThis was a retrospective analysis of two prospective studies investigating oocyte cryopreservation and ovarian tissue cryopreservation in newly diagnosed early breast cancer patients...
October 10, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29040187/palliative-radiation-therapy-for-recurrent-ovarian-cancer-efficacy-and-predictors-of-clinical-response
#6
Ginger Jiang, Tracy Balboni, Allison Taylor, Joyce Liu, Larissa J Lee
OBJECTIVE: This study aimed to report response rates and predictors of response to palliative radiotherapy (RT) for recurrent ovarian cancer. METHODS/MATERIALS: Database review identified 64 patients with symptomatic ovarian cancer recurrence who received a total of 76 courses of RT for 103 indications from March 2003 to August 2014. Radiotherapy indications were pain (44%), bleeding (32%), obstruction (15%), and other (9%). Responses were categorized as complete, partial, or none; all response (AR) was the sum of complete and partial responses...
October 17, 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/28984674/targeted-genomic-profiling-reveals-recurrent-kras-mutations-in-mesonephric-like-adenocarcinomas-of-the-female-genital-tract
#7
Jelena Mirkovic, Marie McFarland, Elizabeth Garcia, Lynette M Sholl, Neal Lindeman, Laura MacConaill, Fei Dong, Michelle Hirsch, Marisa R Nucci, Charles M Quick, Christopher P Crum, W Glenn McCluggage, Brooke E Howitt
Mesonephric adenocarcinoma most commonly arises in the cervix and is presumed to be derived from normal or hyperplastic mesonephric remnants. It is characterized by recurrent KRAS mutations and lack of PIK3CA/PTEN alterations. Adenocarcinomas of the uterine corpus and ovary characterized by morphologic and immunophenotypic similarities to mesonephric adenocarcinoma have been reported. The pathogenesis of these tumors, which have been designated "mesonephric-like adenocarcinomas" is unknown, and it has been debated whether these represent mesonephric adenocarcinomas that arise in the endometrium/ovary or endometrioid adenocarcinomas that closely mimic mesonephric adenocarcinoma...
October 3, 2017: American Journal of Surgical Pathology
https://www.readbyqxmd.com/read/28921520/anti-m%C3%A3-llerian-hormone-and-risk-of-ovarian-cancer-in-nine-cohorts
#8
Seungyoun Jung, Naomi Allen, Alan A Arslan, Laura Baglietto, Aurelio Barricarte, Louise A Brinton, Brian L Egleston, Roni T Falk, Renée T Fortner, Kathy J Helzlsouer, Yutang Gao, Annika Idahl, Rudolph Kaaks, Vittorio Krogh, Melissa A Merritt, Eva Lundin, N Charlotte Onland-Moret, Sabina Rinaldi, Helena Schock, Xiao-Ou Shu, Patrick M Sluss, Paul N Staats, Carlotta Sacerdote, Ruth C Travis, Anne Tjønneland, Antonia Trichopoulou, Shelley S Tworoger, Kala Visvanathan, Elisabete Weiderpass, Anne Zeleniuch-Jacquotte, Joanne F Dorgan
Animal and experimental data suggest that anti-Müllerian hormone (AMH) serves as a marker of ovarian reserve and inhibits the growth of ovarian tumors. However, few epidemiologic studies have examined the association between AMH and ovarian cancer risk. We conducted a nested case-control study of 302 ovarian cancer cases and 336 matched controls from nine cohorts. Prediagnostic blood samples of premenopausal women were assayed for AMH using a picoAMH enzyme-linked immunosorbent assay. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using multivariable-adjusted conditional logistic regression...
September 18, 2017: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/28904505/embryo-cryopreservation-following-in-vitro-maturation-for-fertility-preservation-in-a-woman-with-mullerian-adenosarcoma-a-case-report
#9
Mehdi Mohsenzadeh, Mohammad A Khalili, Nasim Tabibnejad, Nahid Yari, Azam Agha-Rahimi, Mojgan Karimi-Zarchi
In-vitro maturation (IVM) of the immature oocytes recovered from the surgically removed ovarian tissue has been considered as a process for fertility preservation in patients with cancer. Fertility preservation for a woman with Mullerian adenocarcinoma. A 37-year-old woman with Mullerian adenocarcinoma was a candidate for ovarian resection. The immature oocytes were retrieved after ovarian resection from a 37-year-old woman with Mullerian adenocarcinoma. The oocytes underwent IVM and were fertilized using intracytoplasmic sperm injection (ICSI)...
April 2017: Journal of Human Reproductive Sciences
https://www.readbyqxmd.com/read/28878359/directed-differentiation-of-human-induced-pluripotent-stem-cells-into-fallopian-tube-epithelium
#10
Nur Yucer, Marie Holzapfel, Tilley Jenkins Vogel, Lindsay Lenaeus, Loren Ornelas, Anna Laury, Dhruv Sareen, Robert Barrett, Beth Y Karlan, Clive N Svendsen
The fallopian tube epithelium (FTE) has been recognized as a site of origin of high-grade serous ovarian cancer (HGSC). However, the absence of relevant in vitro human models that can recapitulate tissue-specific architecture has hindered our understanding of FTE transformation and initiation of HGSC. Here, induced pluripotent stem cells (iPSCs) were used to establish a novel 3-dimensional (3D) human FTE organoid in vitro model containing the relevant cell types of the human fallopian tube as well as a luminal architecture that closely reflects the organization of fallopian tissues in vivo...
September 6, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28877720/reduced-ovarian-reserve-in-young-early-breast-cancer-patients-preliminary-data-from-a-prospective-cohort-trial
#11
Antonia Wenners, Jana Grambach, Juliane Koss, Nicolai Maass, Walter Jonat, Andreas Schmutzler, Christoph Mundhenke
BACKGROUND: The numerous side effects of chemotherapy in patients with breast cancer are well known. However, the precise effects of chemotherapy on ovarian function in premenopausal women are poorly investigated. The patients are at risk of developing sexual hormone deficiency and impaired fertility. This prospective cohort study addresses predictive parameters of ovarian reserve after chemotherapy. METHODS: Fifty-one premenopausal women (28-46 years) with primary breast cancer were included in the trial...
September 6, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28873086/anti-mullerian-hormone-and-endometrial-cancer-a-multi-cohort-study
#12
Renée T Fortner, Helena Schock, Seungyoun Jung, Naomi E Allen, Alan A Arslan, Louise A Brinton, Brian L Egleston, Roni T Falk, Marc J Gunter, Kathy J Helzlsouer, Annika Idahl, Theron S Johnson, Rudolf Kaaks, Vittorio Krogh, Eva Lundin, Melissa A Merritt, Carmen Navarro, N Charlotte Onland-Moret, Domenico Palli, Xiao-Ou Shu, Patrick M Sluss, Paul N Staats, Antonia Trichopoulou, Elisabete Weiderpass, Anne Zeleniuch-Jacquotte, Wei Zheng, Joanne F Dorgan
BACKGROUND: The Mullerian ducts are the embryological precursors of the female reproductive tract, including the uterus; anti-Mullerian hormone (AMH) has a key role in the regulation of foetal sexual differentiation. Anti-Mullerian hormone inhibits endometrial tumour growth in experimental models by stimulating apoptosis and cell cycle arrest. To date, there are no prospective epidemiologic data on circulating AMH and endometrial cancer risk. METHODS: We investigated this association among women premenopausal at blood collection in a multicohort study including participants from eight studies located in the United States, Europe, and China...
October 24, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28732324/anti-m%C3%A3-llerian-hormone-amh-levels-in-premenopausal-breast-cancer-patients-treated-with-taxane-based-adjuvant-chemotherapy-a-translational-research-project-of-the-success-a-study
#13
Elisabeth Trapp, J Steidl, B Rack, M S Kupka, U Andergassen, J Jückstock, A Kurt, T Vilsmaier, A de Gregorio, N de Gregorio, M Tzschaschel, C Lato, A Polasik, H Tesch, A Schneeweiss, M W Beckmann, P A Fasching, W Janni, V Müller
BACKGROUND: Premenopausal women undergoing chemotherapy are at high risk for premature ovarian failure and its long-term consequences. Data on potential markers to evaluate ovarian reserve pre- and posttreatment are limited. Anti-Müllerian hormone (AMH) known for ovarian reserve in reproductive medicine could be a surrogate marker and was assessed in premenopausal breast cancer patients of the SUCCESS A study (EUDRA-CT no. 2005-000490-21). METHODS: We identified 170 premenopausal patients, age ≤ 40 years at trial entry, who received FEC-Doc as taxane-anthracylince based chemotherapy...
July 18, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28721129/anti-m%C3%A3-llerian-hormone-amh-as-a-good-predictor-of-time-of-menopause
#14
REVIEW
Aleksandra Kruszyńska, Jadwiga Słowińska-Srzednicka
Anti-Müllerian hormone (AMH) in women is secreted by granulosa cells in late preantral and small antral follicles. AMH seems to be a very stable marker having some advantages over other biochemical and biophysical markers and is very useful in the assessment of ovarian reserve. AMH measurement may be used in cases of premature ovarian failure, including iatrogenic, due to treatment for cancer, hypogonadotropic hypogonadism, and lastly, in polycystic ovary syndrome (PCOS). It is also a very specific marker of ovarian tumors - folliculomas...
June 2017: Przeglad Menopauzalny, Menopause Review
https://www.readbyqxmd.com/read/28716033/current-status-of-tertiary-debulking-surgery-and-prognosis-after-secondary-debulking-surgery-for-recurrent-m%C3%A3-llerian-epithelial-cancer-in-japan-a-retrospective-analysis-of-164-patients-kcog-g1402
#15
Tomoko Hirakawa, Takeo Minaguchi, Yoshio Itani, Yuka Kasamatsu, Saki Murase, Shoko Sakurada, Hiroaki Nagano, Kazuhiro Takehara, Tomohiko Tsuruta, Atsushi Arakawa, Kouichiro Kawano, Hiroshi Tsubamoto, Takashi Ushiwaka, Taisuke Mori, Kana Iwai, Motoaki Saito, Hiroyuki Morisawa, Fumitaka Saito, Kenta Yoshida, Masanori Kaneuchi, Hiroki Sato, Kimihiko Ito, Kaei Nasu
BACKGROUND: This study aimed to evaluate the current status of secondary debulking surgery (SDS) and tertiary debulking surgery (TDS; performed for recurrence after SDS) and to assess the overall survival after recurrence of Müllerian epithelial cancer in Japan. We also evaluated the data of patients who underwent a fourth debulking surgery (i.e., quaternary debulking surgery (QDS)). METHODS: We conducted a retrospective study of 164 patients with recurrent Müllerian epithelial cancers (i...
July 17, 2017: World Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28678427/clear-cell-and-endometrioid-carcinomas-are-their-differences-attributable-to-distinct-cells-of-origin
#16
COMPARATIVE STUDY
Dawn R Cochrane, Basile Tessier-Cloutier, Katherine M Lawrence, Tayyebeh Nazeran, Anthony N Karnezis, Clara Salamanca, Angela S Cheng, Jessica N McAlpine, Lien N Hoang, C Blake Gilks, David G Huntsman
Endometrial epithelium is the presumed tissue of origin for both eutopic and endometriosis-derived clear cell and endometrioid carcinomas. We had previously hypothesized that the morphological, biological and clinical differences between these carcinomas are due to histotype-specific mutations. Although some mutations and genomic landscape features are more likely to be found in one of these histotypes, we were not able to identify a single class of mutations that was exclusively present in one histotype and not the other...
September 2017: Journal of Pathology
https://www.readbyqxmd.com/read/28657229/early-ovarian-cancer-surgery-with-indocyanine-green-guided-targeted-compartmental-lymphadenectomy-tcl-pelvic-part
#17
Rainer Kimmig, Paul Buderath, Peter Rusch, Pawel Mach, Bahriye Aktas
OBJECTIVE: Para-aortic indocyanine-green (ICG)-guided targeted compartmental lymphadenectomy is feasible in early ovarian cancer; systematic pelvic and para-aortic lymphadenectomy could potentially be avoided if thoroughly investigated sentinel nodes could predict whether residual nodes will be involved or free of disease. In contrast to advanced ovarian cancer, where the therapeutic potential of lymphadenectomy will soon be clarified by the results of the Arbeitsgemeinschaft Gynäkologische Onkologie lymphadenectomy in ovarian neoplasms (AGO LION) trial, systematic lymphadenectomy seems to be mandatory for diagnostic and also therapeutic purposes in early ovarian cancer...
September 2017: Journal of Gynecologic Oncology
https://www.readbyqxmd.com/read/28652099/influence-of-adjuvant-chemotherapy-on-anti-m%C3%A3-llerian-hormone-in-women-below-35-years-treated-for-early-breast-cancer
#18
Anne Perdrix, Mathilde Saint-Ghislain, Marie Degremont, Marion David, Zena Khaznadar, Agnès Loeb, Marianne Leheurteur, Frédéric Di Fiore, Florian Clatot
The impact of chemotherapy on fertility appears to be of essential importance for the youngest cancer survivors. The aim of this study was to assess plasma anti-Mullërian hormone (AMH) evolution, using an automated sensitive AMH immunoassay in women younger than 35 years old before and after treatment with adjuvant chemotherapy for early breast cancer. We selected 54 women aged less than 35 years old, at the time of breast cancer diagnosis, who received chemotherapy between 2008 and 2014, and with plasma samples collected from the diagnosis, to 1 year, 3 years and 5 years post-diagnosis...
June 15, 2017: Reproductive Biomedicine Online
https://www.readbyqxmd.com/read/28643088/potential-therapeutic-applications-of-human-anti-m%C3%A3-llerian-hormone-amh-analogues-in-reproductive-medicine
#19
REVIEW
Vitaly A Kushnir, David B Seifer, David H Barad, Aritro Sen, Norbert Gleicher
Members of the transforming growth factor-beta (TGF-beta) superfamily are key regulators of various physiological processes. Anti-Müllerian hormone (AMH) which is also commonly known as Müllerian-inhibiting substance (MIS) is a member of the TGF-beta superfamily and an important regulator of reproductive organ differentiation and ovarian follicular development. While AMH has been used for diagnostic purposes as a biomarker for over 15 years, new potential therapeutic applications of recombinant human AMH analogues are now emerging as pharmacologic agents in reproductive medicine...
June 22, 2017: Journal of Assisted Reproduction and Genetics
https://www.readbyqxmd.com/read/28620623/resolution-of-diffuse-intrahepatic-biliary-strictures-after-chemotherapy-for-metastatic-ovarian-cancer
#20
Daniel Lew, Vinay Sundaram, Brad D Barrows, Simon K Lo, Srinivas Gaddam
Sclerosing cholangitis and cholestatic jaundice secondary to metastatic disease is a rare complication. We report a rare case of secondary sclerosing cholangitis (SSC) due to lymphatic spread from ovarian cancer with complete resolution after chemotherapy. The diagnosis of SSC from metastatic ovarian cancer was clinically challenging, as endoscopic retrograde cholangiopancreatography revealed irregular hepatic ducts consistent with sclerosing cholangitis, but it did not identify any malignant cells. The final diagnosis was made with liver biopsy revealing high-grade metastatic Mullerian carcinoma...
2017: ACG Case Reports Journal
keyword
keyword
87375
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"